Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22329663 | 0.99 | PRKDC (0.35) | PRKDCLIMK1ALOX5LIMK2MEN1 | |
| SCHEMBL22195436 | 0.99 | PRKDC (0.35) | PRKDCLIMK1ALOX5LIMK2MEN1 | |
| SCHEMBL22329563 | 0.99 | PRKDC (0.35) | PRKDCLIMK1ALOX5LIMK2MEN1 | |
| SCHEMBL25017018 | 0.99 | PRKDC (0.35) | PRKDCLIMK1ALOX5LIMK2MEN1 | |
| SCHEMBL22329654 | 0.99 | PRKDC (0.35) | PRKDCLIMK1ALOX5LIMK2MEN1 | |
| SCHEMBL25017017 | 0.98 | PRKDC (0.35) | PRKDCLIMK1ALOX5MEN1KMT2A | |
| SCHEMBL22195751 | 0.98 | PRKDC (0.36) | PRKDCLIMK1ALOX5LIMK2MEN1 | |
| SCHEMBL22329541 | 0.98 | PRKDC (0.36) | PRKDCLIMK1ALOX5LIMK2MEN1 | |
| SCHEMBL22329214 | 0.98 | PRKDC (0.37) | PRKDCLIMK1ALOX5MEN1KMT2A | |
| SCHEMBL25016539 | 0.97 | PRKDC (0.35) | PRKDCLIMK1ALOX5LIMK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578076-B2 | Heterocyclic compound and organic light emitting device using the same | LG CHEM, LTD. (KR) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578076-B2 | Heterocyclic compound and organic light emitting device using the same | CYBA, SUN2, TMEM109 | PRKDC 4652/4885LIMK1 389/4885ALOX5 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.